A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma

This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease.

Inclusion Criteria:

• Histologically or cytologically confirmed cutaneous malignant melanoma
• Clinical evidence of metastatic disease and/or unresectable regional lymphatic disease and/or extensive in transit recurrent disease
• Measurable and/or evaluable lesions according to RECIST

Exclusion Criteria:

• Prior interferon alfa and/or cytokine therapy for metastatic disease
• Prior chemotherapy for metastatic disease
• Brain metastases
• Chronic daily treatment with high-dose aspirin (more than 325 milligrams per day)
• Other co-existing malignancies or malignancies diagnosed within the past 5 years with the exception of basal cell cancer or cervical cancer in situ